Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13892MR)

This product GTTS-WQ13892MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13892MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8400MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ757MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ9266MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ5175MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ10458MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ13682MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ10750MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW